Sen. Lesser Highlights CT’s Generic GLP-1 Legislation at National Conference
Today, State Senator Matt Lesser, Senate Chair of the Human Services Committee, spoke at the National Academy for State Health Policy (NASHP) Annual Health Policy Conference in San Diego on Connecticut’s recently enacted bipartisan prescription drug law, which puts Connecticut in the front of the pack of states in controlling drug costs.
He was invited to present as part of The Wave of High Drug Prices and Strategies to Tame Them panel.
Senator Lesser shared details of his recently enacted legislation that implemented many of the recommendations of the bipartisan Prescription Drug Task Force that he co-chaired. The conversation explored the first of its kind provision that allows Connecticut to partner with a generic GLP-1 manufacturer, engage bulk purchasing, cap the cost of generic drugs, reform pharmacy benefit-mangers (PBMS), and how to build bipartisan collaboration on the issue of prescription drug prices.
“It is an honor to be here with colleagues from across the country to present on an issue that affects our constituents in every state and every county,” said Sen. Lesser. “I am really proud of the first of its kind legislation we passed in Connecticut, allowing the state to partner with generic drug producers to make our own life-saving yet wildly expensive drugs like GLP-1s, cap the price of generics and pass real reforms for PBM middlemen. I hope that other states will follow suit and together we can push back against greedy health care behemoths and create real relief for our residents.”
NASHP is a bipartisan network that brings senior state level policy leaders together from around the country.